He aha ka Orforgliron?

ʻO Orforglipron kahi maʻi maʻi type 2 hou a me ka lāʻau lapaʻau hoʻohaʻahaʻa kaumaha ma lalo o ka hoʻomohala ʻana a ke manaʻo ʻia nei e lilo i mea ʻokoʻa waha i nā lāʻau injectable. No ka glucagon-like peptide-1 (GLP-1) receptor agonist ʻohana a ua like ia me ka mea maʻamau i hoʻohana ʻia ʻo Wegovy (Semaglutide) a me Mounjaro (Tirzepatide). Loaʻa iā ia nā hana o ka hoʻoponopono ʻana i ke kō koko, kaohi ʻana i ka ʻai a me ka hoʻonui ʻana i ka satiety, ma laila e kōkua ai i ka mālama ʻana i ke kaumaha a me ke kō koko koko.

ʻAʻole like me ka hapa nui o nā lāʻau lapaʻau GLP-1, aia ka pono kūʻokoʻa o Orforglipron i kāna ʻano papa papa waha i kēlā me kēia lā ma mua o ka hoʻokele ʻana i kēlā me kēia pule. Ua hoʻonui nui kēia ʻano hoʻokele i ka mālama ʻana a me ka maʻalahi o ka hoʻohana ʻana i nā mea maʻi, e hōʻike ana i kahi holomua koʻikoʻi no ka poʻe makemake ʻole i nā injections a i ʻole ka manaʻo kūʻē i nā injections.

I nā hoʻokolohua lapaʻau, hōʻike ʻo Orforglipron i nā hopena maikaʻi loa o ka pohō kaumaha. Hōʻike nā ʻikepili i nā poʻe i lawe iā Orforglipron i kēlā me kēia lā no 26 mau pule i ʻike ʻia he awelika kaumaha o ka 8% a 12%, e hōʻike ana i kona pono nui i ka mālama kaumaha. ʻO kēia mau hopena i hoʻolilo iā Orforglipron i manaʻolana hou no ka mālama ʻana i ka maʻi diabetes type 2 a me ka momona, a hōʻike pū kekahi i kahi ʻano koʻikoʻi i ke kahua o nā lāʻau lapaʻau GLP-1, ke neʻe nei mai ka injectable a i nā ʻano dosage waha.